Jointown Pharmaceutical Group Co Ltd
SSE:600998

Watchlist Manager
Jointown Pharmaceutical Group Co Ltd Logo
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Watchlist
Price: 5.53 CNY -2.12% Market Closed
Market Cap: 27.9B CNY
Have any thoughts about
Jointown Pharmaceutical Group Co Ltd?
Write Note

Jointown Pharmaceutical Group Co Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jointown Pharmaceutical Group Co Ltd
Other Current Assets Peer Comparison

Comparables:
1099
601607
C
600511
000963
Q
301015

Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Other Current Assets
ÂĄ13B
CAGR 3-Years
67%
CAGR 5-Years
48%
CAGR 10-Years
23%
Sinopharm Group Co Ltd
HKEX:1099
Other Current Assets
ÂĄ29.4B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
14%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Other Current Assets
ÂĄ5.2B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
15%
C
China National Medicines Corp Ltd
SSE:600511
Other Current Assets
ÂĄ253.7m
CAGR 3-Years
9%
CAGR 5-Years
-8%
CAGR 10-Years
9%
Huadong Medicine Co Ltd
SZSE:000963
Other Current Assets
ÂĄ588.2m
CAGR 3-Years
33%
CAGR 5-Years
-1%
CAGR 10-Years
6%
Q
Qingdao Baheal Medical Inc
SZSE:301015
Other Current Assets
ÂĄ362.6m
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
N/A

See Also

What is Jointown Pharmaceutical Group Co Ltd's Other Current Assets?
Other Current Assets
13B CNY

Based on the financial report for Jun 30, 2024, Jointown Pharmaceutical Group Co Ltd's Other Current Assets amounts to 13B CNY.

What is Jointown Pharmaceutical Group Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
23%

Over the last year, the Other Current Assets growth was 2%. The average annual Other Current Assets growth rates for Jointown Pharmaceutical Group Co Ltd have been 67% over the past three years , 48% over the past five years , and 23% over the past ten years .

Back to Top